Owen, Dawn

Thymic tumors are exceedingly rare, and most available treatment data come from pooled retrospective analyses. The cornerstone of management is resection, with the use of systemic therapy and radiation therapy (RT) as tools to facilitate surgery and prevent recurrence, or as primary management in unresectable or metastatic disease. Despite the challenges of managing such rare entities, a number of advances have occurred in surgical techniques, systemic therapy, and RT indications and technologies. There is a growing shift toward minimally invasive surgical techniques and the use of surgery to treat pleural metastases, the most common site of recurrence in thymic tumors. Systemic therapy options now include targeted therapies and immunotherapy. RT continues to evolve as new data clarify postoperative recurrence risks and as more targeted treatment approaches become available. Achieving optimal outcomes relies on multidisciplinary care that thoughtfully individualizes and integrates multimodality treatments.